| Targeting gene expression to hypoxic tumor cells GU Dachs, AV Patterson, JD Firth, PJ Ratcliffe, KMS Townsend, ... Nature medicine 3 (5), 515-520, 1997 | 479 | 1997 |
| Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix R Airley, J Loncaster, S Davidson, M Bromley, S Roberts, A Patterson, ... Clinical cancer research 7 (4), 928-934, 2001 | 429 | 2001 |
| Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ... Clinical Cancer Research 13 (13), 3922-3932, 2007 | 264 | 2007 |
| Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 F Meng, JW Evans, D Bhupathi, M Banica, L Lan, G Lorente, JX Duan, ... Molecular cancer therapeutics 11 (3), 740-751, 2012 | 229 | 2012 |
| Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia CP Guise, AM Mowday, A Ashoorzadeh, R Yuan, WH Lin, DH Wu, ... Chinese journal of cancer 33 (2), 80, 2014 | 202 | 2014 |
| The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 CP Guise, MR Abbattista, RS Singleton, SD Holford, J Connolly, ... Cancer research 70 (4), 1573-1584, 2010 | 192 | 2010 |
| Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase AV Patterson, H Zhang, A Moghaddam, R Bicknell, DC Talbot, IJ Stratford, ... British journal of cancer 72 (3), 669-675, 1995 | 172 | 1995 |
| Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility EM Williams, RF Little, AM Mowday, MH Rich, JVE Chan-Hyams, ... Biochemical journal 471 (2), 131-153, 2015 | 149 | 2015 |
| Structure− activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine MP Hay, SA Gamage, MS Kovacs, FB Pruijn, RF Anderson, AV Patterson, ... Journal of medicinal chemistry 46 (1), 169-182, 2003 | 139 | 2003 |
| Bystander or no bystander for gene directed enzyme prodrug therapy GU Dachs, MA Hunt, S Syddall, DC Singleton, AV Patterson Molecules 14 (11), 4517-4545, 2009 | 137 | 2009 |
| Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed Y Yosaatmadja, S Silva, JM Dickson, AV Patterson, JB Smaill, ... Journal of structural biology 192 (3), 539-544, 2015 | 133 | 2015 |
| Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 GA Prosser, JN Copp, SP Syddall, EM Williams, JB Smaill, WR Wilson, ... Biochemical pharmacology 79 (5), 678-687, 2010 | 129 | 2010 |
| Novel chimeric gene promoters responsive to hypoxia and ionizing radiation O Greco, B Marples, GU Dachs, KJ Williams, AV Patterson, SD Scott Gene therapy 9 (20), 1403-1411, 2002 | 128 | 2002 |
| Enzymology of tirapazamine metabolism: a review AV Patterson, MP Saunders, EC Chinje, LH Patterson, IJ Stratford Anti-cancer drug design 13 (6), 541-573, 1998 | 117 | 1998 |
| Cancer chemotherapy and drug metabolism DS Riddick, C Lee, S Ramji, EC Chinje, RL Cowen, KJ Williams, ... Drug Metabolism and Disposition 33 (8), 1083-1096, 2005 | 115 | 2005 |
| Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233) AV Patterson, HM Barham, EC Chinje, GE Adams, AL Harris, IJ Stratford British journal of cancer 72 (5), 1144-1150, 1995 | 112 | 1995 |
| Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials L Spiegelberg, R Houben, R Niemans, D de Ruysscher, A Yaromina, ... Clinical and translational radiation oncology 15, 62-69, 2019 | 110 | 2019 |
| Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 AV Patterson, MP Saunders, EC Chinje, DC Talbot, AL Harris, IJ Strafford British journal of cancer 76 (10), 1338-1347, 1997 | 109 | 1997 |
| 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT NA Helsby, DM Ferry, AV Patterson, SM Pullen, WR Wilson British journal of cancer 90 (5), 1084-1092, 2004 | 108 | 2004 |
| A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors MB Jameson, D Rischin, M Pegram, J Gutheil, AV Patterson, WA Denny, ... Cancer chemotherapy and pharmacology 65, 791-801, 2010 | 105 | 2010 |
